# BPC-157: Research Overview — Peptide Research Alliance > A structured literature summary of BPC-157 (Body Protection Compound 157): mechanism, pharmacokinetics, animal-model findings, reported effects, safety cautions, and regulatory status. Peer-reviewed citations throughout. Body Protection Compound 157 — a 15-amino-acid gastric pentadecapeptide whose repair signals in animals track most consistently with the growth of new blood vessels into damaged tissue. ## The short version BPC-157 stands for **Body Protection Compound 157**. It is a synthetic peptide fifteen amino acids long, derived from a sequence found in a human gastric juice protein. In animal studies — overwhelmingly rats — it appears to speed healing in multiple tissue types: tendons, gut lining, muscle, and nerve [5][6]. The most consistent mechanistic explanation is that it stimulates the growth of new blood vessels into injured tissue (angiogenesis), particularly through the VEGFR2-Akt-eNOS signaling pathway [4]. Here is the honest accounting. Almost all of this evidence is preclinical. As of 2025 reviews, only three small human pilot studies exist, and no large, rigorous controlled human trials have been conducted [2]. A 2025 first-in-human IV safety pilot in two healthy adults found no adverse events, but that tiny n makes it a preliminary report, not proof of safety or efficacy [1]. BPC-157 is not an approved drug anywhere, is prohibited in organized sport by the World Anti-Doping Agency, and popular online claims about weight loss, muscle building, or testosterone effects are not supported by the published science [2]. This page summarizes what was studied; it does not recommend use or list human doses. ## What it is BPC-157 is a *stable gastric pentadecapeptide* — the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, fifteen amino acids, drawn from a cytoprotective protein in gastric juice. Its research designations include PL 14736, PLD-116, PL-10, and Bepecin (a research designation). Molecular formula C62H98N16O22. It is a *synthetic* compound — not extracted from a natural source — and it is not an approved medicine. In the United States, the FDA placed BPC-157 in a category of substances it identified as not eligible for pharmacy compounding under Section 503A, following a regulatory review. It is marketed strictly as a research chemical for laboratory use. ## How it works The best-characterized mechanism is **pro-angiogenic signaling via VEGFR2**: BPC-157 up-regulates VEGFR2 expression and promotes receptor internalization, with downstream activation of the VEGFR2-Akt-eNOS pathway [4]. In a 2017 study using chick chorioallantoic membrane, rat hindlimb ischemia, and human vascular endothelial cells, this pathway produced increased vessel density in vitro and accelerated blood-flow recovery in vivo; effects were blocked by endocytosis inhibition, implicating receptor internalization as mechanistically necessary [4]. Additional pathways described in the preclinical literature include FAK-paxillin signaling (cell migration), growth-hormone-receptor sensitization in tendon fibroblasts, and modulation of the nitric-oxide system and neurotransmitter systems including serotonergic and dopaminergic circuits [7]. A 2022 pharmacokinetic characterization in rats and beagle dogs found a short elimination half-life (< 30 min) and modest intramuscular bioavailability (approximately 14–19% in rats, 45–51% in dogs) [3]. ## What the research shows **Pharmacokinetics (rats and dogs, 2022) [3]:** BPC-157 shows linear pharmacokinetics, a short elimination half-life, modest intramuscular bioavailability, and rapid breakdown into amino-acid metabolites. This is the first formal PK/ADME characterization of the compound. **Angiogenesis mechanism (multi-model, 2017) [4]:** Pro-angiogenic activity via VEGFR2 up-regulation and internalization, with downstream VEGFR2-Akt-eNOS activation. Demonstrated in chick chorioallantoic membrane, rat hindlimb ischemia, and human vascular endothelial cells. Increased vessel density and accelerated ischemic muscle blood-flow recovery. **Gastric cytoprotection (Wistar rats, 2004) [5]:** BPC-157 reduced gastric ulcer area and accelerated healing; intramuscular delivery outperformed intragastric. Ulcer-formation inhibition ratio 45.7–65.6% at higher doses, with accelerated glandular-epithelium rebuilding and granulation-tissue formation. **Achilles tendon healing (Wistar rats, 2003) [6]:** Accelerated healing of a fully transected Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures. Also stimulated tendocyte outgrowth in vitro, suggesting both a systemic and direct cellular effect. **Brain-gut axis and neurotransmitter modulation (review, 2016) [7]:** Positions BPC-157 as a brain-gut-axis mediator, modulating nigrostriatal serotonin and dopaminergic systems, implicating Egr-1, NAB2, FAK-paxillin, and JAK-2 pathways. **First-in-human IV safety pilot (2025) [1]:** Intravenous BPC-157 up to 20 mg in two healthy adults (ages 58 and 68) was well tolerated with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers. The authors note this is a preliminary report; the sample size is two. **2025 narrative review [2]:** Concludes that BPC-157 has broad preclinical support, but human data are extremely limited — only three pilot studies — and rigorous large-scale trials are lacking. Recommends treating BPC-157 as investigational and using with caution given regulatory controversy and non-regulated availability. ## Reported effects, cautions, and safety **Community-reported effects (anecdotal, not clinical evidence)** In research-use communities, the most commonly reported experience with BPC-157 is **faster recovery from tendon, ligament, and joint injuries** — people describe stubborn connective-tissue problems improving within one to three weeks. This is the primary reason the compound appears in research-use forums. Other frequently reported benefits include less joint stiffness and pain, improved digestive or gut symptoms, and — occasionally — better sleep and mood. Adverse effects most commonly mentioned include brief injection-site stinging or redness, mild nausea (more common with oral than injectable routes), and transient fatigue in the first week. Less commonly, users report headache, dizziness shortly after injection, or a flush of warmth — effects consistent with the compound's reported actions on blood-vessel tone. All of these are anecdotal self-reports from uncontrolled research-use contexts, not data from controlled trials. **Safety cautions (citation-grounded)** - *Thin human evidence base:* Almost everything known about BPC-157 comes from rodent studies. As of 2025, only a handful of small, uncontrolled human pilot reports exist [2]. Animal results should not be read as established human benefits. - *Single research group:* A large share of the foundational literature was produced by one research group, and independent replication is limited. Newer reviewers explicitly flag this [2]. - *Pro-angiogenic mechanism raises a theoretical cancer concern:* BPC-157's repair effects are tied to VEGFR2-mediated angiogenesis [4] and the nitric-oxide system. Because tumors also depend on angiogenesis, there is a mechanism-based concern about use in people with active or suspected malignancy. - *Possible interaction with serotonin-affecting medicines:* In rodent work BPC-157 changes brain serotonin activity [7]. This creates a theoretical concern about combinations with serotonin-raising medicines; this caution is preclinical, not based on human interaction data. - *Growth-signaling activity and unknown long-term effects:* BPC-157 promotes growth-hormone-receptor signaling in tendon cells. Any agent that modulates growth pathways carries a theoretical question about long-term tissue effects; there are no long-term human safety data. - *WADA prohibition:* BPC-157 is prohibited in sport at all times under the WADA non-approved-substances category. Athletes subject to testing face sanctions. - *Unstudied in pregnancy, breastfeeding, and children.* ## Where it fits in this research desk BPC-157 is the *lead compound* on this desk — the most-studied research peptide in the tissue-repair and cytoprotection category. Its decades of preclinical work make it a reference point for understanding what research peptides look like at deep animal-model development stages, and its very thin human data file illustrates why the distance from rodent evidence to approved human medicine is measured in years of clinical trials, not individual pilots. For researchers exploring the adjacent compounds, [GHK-Cu](/ghk-cu) represents the repair category with the most human (topical) evidence. [Ipamorelin](/ipamorelin) addresses tissue recovery from the GH-axis side. [Compare all five compounds](/compare) for a side-by-side view of class, evidence maturity, and regulatory status. --- An independent literature digest of peer-reviewed research — definitional, cited, and free of products, prescriptions, and dosing recommendations.